ABSTRACT
Extracorporeal photopheresis (ECP) is a cell-based immunemodulatory therapy, which was first reported by Edelson et al. (1987) for the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL). This technique is now used to treat CTCL as well as other T-cell-mediated conditions, including acute and chronic graft-versus-host disease (GvHD) and rejection of solid organ transplants. This chapter will summarize the research work undertaken to elucidate the mechanism of action of ECP and outline the technical procedure and its safety profile. The role of ECP in the treatment of CTCL, GvHD, and other conditions will also be discussed.
